First Platform Biologic: ST266
Noveome seeks to treat injuries and disease with ST266, a product that contains a unique combination of biologically active proteins and factors.
Noveome has 50 issued U.S. patents covering ST266 and the cells and process for producing it as well as methods of use and many other pending patent applications. In addition, Noveome has over 40 granted patents and several pending applications in major global markets including Europe, Japan, China, and Canada.
ST266 has been developed with the support of the U.S. Department of Defense and has demonstrated potential to improve patient outcomes in neurologic, ophthalmic, respiratory, gastrointestinal, and other diseases and conditions.
ST266 is a novel, complex, cell-free biologic produced by culturing a unique population of cells derived from the amnion of the human placenta under proprietary conditions. ST266 contains hundreds of biologically active proteins and other factors involved in cellular healing, protection of the brain and nerves, and modulation of inflammation. Numerous biologic components in ST266 are present at physiologic concentrations which together function synergistically. The resulting ST266 product is anti-inflammatory, neuroprotective, and anti-apoptotic, all properties that preserve cellular and vascular integrity.
ST266 serves as a platform biologic with the potential to address a wide range of conditions across multiple therapeutic indications which are less likely to respond to the traditional “one drug, one target” therapeutic model.
One scalable manufacturing process is used to produce ST266 for all indications. A drug master file has been submitted to the FDA supporting all ST266 investigational new drug (IND) applications, both existing and future, and consolidates all the chemistry, manufacturing, and controls (CMC) information from ST266 starting material through drug substance.
Noveome has utilized innovative approaches for delivering ST266 to targeted tissues. In collaboration with leading academic, medical and military research institutions, we are developing targeted intranasal delivery to treat the optic nerve and brain, inhaled delivery for the lung, intracameral and topical delivery for the eye, and enteral delivery for the gastrointestinal tract.
Our therapeutic approach is to develop ST266 for the treatment of serious diseases by taking advantage of its multiple activities:
ST266 restores nerve function, supports nerve cell survival, and decreases the rate of demyelination.
ST266 modulates the inflammatory response by decreasing vascular permeability, immune cell infiltration, and edema.
ST266 improves function in damaged cells. It increases proliferation, reduces apoptosis, and helps restore homeostasis.
ST266 facilitates healing in impaired conditions, such as those associated with elderly or diabetic patients. ST266 has been shown to facilitate processes necessary for cellular healing such as the deposition, alignment, and cross-linking of collagen fibers and matrix. www.ncbi.nlm.nih.gov
Our therapeutic approach has potential to be applied across a wide range of disease indications to improve patient outcomes. Learn More about our Pipeline »